Multitarget stool DNA testing for colorectal-cancer screening

New England Journal of Medicine

Volumn 370, Issue 14, 2014, Pages 1287-1297

  Imperiale, Thomas F ^a,b   Ransohoff, David F ^c   Itzkowitz, Steven H ^d   Levin, Theodore R ^e   Lavin, Philip ^f   Lidgard, Graham P ^g   Ahlquist, David A ^h   Berger, Barry M ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c IL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f Boston Biostatistics Research Foundation   (United States)

^g Exact Sciences Corporation   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; HEMOGLOBIN; K RAS PROTEIN; ONCOPROTEIN; OSTEOGENIN; PROTEIN NDRG4; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER STAGING; COLON POLYP; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; DYSPLASIA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECES ANALYSIS; GENE MUTATION; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTITARGET STOOL DNA TESTING; MUTATIONAL ANALYSIS; NON INVASIVE PROCEDURE; PRECANCER; PRIORITY JOURNAL; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ACTINS; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 3; CHROMOSOME ABERRATIONS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC TECHNIQUES; MALE; MASS SCREENING; MIDDLE AGED; MUSCLE PROTEINS; MUTATION; NERVE TISSUE PROTEINS; OCCULT BLOOD; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84897509377     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1311194     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
3. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95. (Pubitemid 351615355)
4. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol 2009;104:739-50. [Erratum, Am J Gastroenterol 2009;104:1613.]
5. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008;27:697-712. (Pubitemid 351406306)
6. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med 2010;7(11):e1000370.
7. Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 2013;108:120-32.
8. Vital signs: colorectal cancer screening test use - United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:881-8.
9. Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 2012;44:80-8.
10. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-50.
11. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14. (Pubitemid 39665324)
12. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058-65. (Pubitemid 36751091)
13. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006;15:1115-9.
14. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012;142:248-56.
15. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008;103:2862-70.
16. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 2013;11:1313-8.
17. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009;27:858-63.
18. Aronchick CA, Lipshutz WH, Wright SH, Dufrayne F, Bergman G. A novel tableted purgative for colonoscopic preparation: efficacy and safety comparisons with Colyte and Fleet Phospho-Soda. Gastrointest Endosc 2000;52:346-52.
19. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. Chicago: American Joint Committee on Cancer, 2009.
20. OC-Auto Micro 80 FOB Test (product insert). Cortland Manor, NY: Polymedco (http://www.fobt-tests.com).
21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43. (Pubitemid 13033817)
22. Bardan E, Bat L, Melzer E, Shemesh E, Bar-Meir S. Colonoscopic resection of large colonic polyps - a prospective study. Isr J Med Sci 1997;33:777-80. (Pubitemid 28041095)
23. Christie JP. Colonoscopic excision of large sessile polyps. Am J Gastroenterol 1977;67:430-8. (Pubitemid 8179547)
24. Lieberman D, Moravec M, Holub J, Michaels L, Eisen G. Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. Gastroenterology 2008;135:1100-5.
25. Nivatvongs S, Snover DC, Fang DT. Piecemeal snare excision of large sessile colon and rectal polyps: is it adequate? Gastrointest Endosc 1984;30:18-20. (Pubitemid 14179584)
26. Kahi CJ, Li X, Eckert GJ, Rex DK. High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. Gastrointest Endosc 2012;75:515-20.
27. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107:1315-29.
28. Corley DA, Jensen CD, Marks AR, et al. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol 2013;11:172-80.
29. Ahlquist DA. Molecular detection of colorectal neoplasia. Gastroenterology 2010;138:2127-39.
30. Ahlquist DA, Taylor WR, Yab TC, et al. Aberrantly methylated gene marker levels in stool: effects of demographic, exposure, body mass, and other patient characteristics. J Mol Biomark Diagn 2012;3(5):e1000133.
31. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8. (Pubitemid 41096630)
32. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
33. Raginel T, Puvinel J, Ferrand O, et al. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology 2013;144:918-25.
34. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37.
35. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening - age to begin, age to stop, and timing of screening intervals: a decision analysis of colorectal cancer screening for the U.S. Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET). Rockville, MD: Agency for Healthcare Research and Quality, March 2009. (AHRQ publication no. 08-05124-EF-2.)
36. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med 2012;172:575-82.